Hydrocortison Panpharma (Hydrocortisone Hydrogen Succinate)

Hydrocortison Panpharma is indicated for several acute and chronic conditions where glucocorticoid activity is required.

• Replacement therapy in primary or secondary adrenal insufficiency.
• Management of acute inflammatory states such as severe arthritis or cellulitis.
• Treatment of circulatory shock where rapid glucocorticoid support is needed.
• Control of severe allergic reactions, including anaphylaxis, when other measures are insufficient.
• Adjunct therapy for refractory asthma exacerbations or other acute bronchospastic events.
• Short‑term anti‑inflammatory support after major surgery to reduce tissue edema.

It is typically administered by a healthcare professional in a hospital or clinic setting.

• Hydrocortisone hydrogen succinate is a pro‑drug of hydrocortisone that, after conversion, binds to intracellular glucocorticoid receptors. The receptor‑ligand complex translocates to the nucleus and modulates gene transcription, up‑regulating anti‑inflammatory proteins such as annexin‑1 and down‑regulating pro‑inflammatory cytokines (e.g., IL‑1, IL‑6, TNF‑α). This results in decreased vascular permeability, inhibition of leukocyte migration, and suppression of the immune response.

Adverse reactions to Hydrocortison Panpharma may vary in frequency and severity. Most reactions are mild and reversible, but clinicians monitor for less common but potentially life‑threatening events.

Common

• Injection site pain, erythema, or swelling at the intramuscular or intravenous site.
• Transient elevation of blood glucose levels, particularly in patients with diabetes.
• Mild gastrointestinal discomfort such as nausea or dyspepsia.
• Fluid retention leading to mild peripheral edema and modest weight gain.

Serious

• Severe allergic reaction (anaphylaxis) presenting with urticaria, bronchospasm, or hypotension.
• Acute adrenal crisis that can occur if the drug is stopped abruptly after extended therapy.
• Increased susceptibility to serious infections due to systemic immunosuppression.

When prescribing Hydrocortison Panpharma, healthcare providers should consider several precautionary measures to ensure safe use.

• Assess adrenal function before initiating therapy and monitor during treatment.
• Use the lowest effective dose for the shortest duration required.
• Caution in patients with uncontrolled diabetes, hypertension, or active infections.
• Avoid abrupt discontinuation after prolonged therapy to prevent adrenal insufficiency.
• Evaluate for possible hypersensitivity to corticosteroids or formulation excipients.
• Consider risk‑benefit in pregnant or breastfeeding women, as safety data are limited.
• Monitor electrolytes and fluid balance, especially in patients receiving high‑dose regimens.

Hydrocortison Panpharma can interact with other medicines, affecting its efficacy or safety profile.

Avoid

• Concurrent use of potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce glucocorticoid concentrations.
• Co‑administration with other systemic corticosteroids, which can increase the risk of systemic side effects.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) because of additive gastrointestinal ulcer risk.
• Anticoagulants, as corticosteroids may enhance anticoagulant effects and increase bleeding tendency.
• Live vaccines, since immunosuppression can diminish vaccine efficacy and raise infection risk.
• Diabetic agents, because glucocorticoids may worsen hyperglycemia.